Physician profile
Sarwan Shaikh
NPI 1699297994
$675.22
in general payments reported to CMS, 2019-2025
14 companies · $581 in 2025
The $581 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $38.63 · 2024: $55.61 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $675.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $215.86 | 2024-2025 | Terlivaz, Acthar |
| Astrazeneca Pharmaceuticals LP | $117.21 | 2024-2025 | Fasenra, Airsupra, Tezspire |
| Janssen Pharmaceuticals, INC | $55.12 | 2023-2024 | Xarelto |
| Glaxosmithkline, LLC. | $45.16 | 2025 | Trelegy Ellipta, Nucala |
| Insmed, INC. | $41.14 | 2025 | Brinsupri, Arikayce |
| Actelion Pharmaceuticals US, INC. | $39.77 | 2025 | Opsumit, Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.73 | 2025 | |
| Alexion Pharmaceuticals, INC. | $24.49 | 2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $22.23 | 2025 | Zerbaxa |
| La Jolla Pharmaceutical Company | $20.29 | 2025 | Zevtera |
| Genzyme Corporation | $19.18 | 2025 | |
| Abiomed | $18.93 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $16.51 | 2025 | Dupixent |
| Verona Pharma, INC. | $14.60 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarwan Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.